ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

0.2669
Delayed Data
As of 3:58pm ET
 +0.0005 / +0.19%
Today’s Change
0.21
Today|||52-Week Range
1.85
-25.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$19.0M

Company Description

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. The company's two of antiviral candidates for treating hepatitis B include phase 2a clinical candidate TXL, a novel, potent analog of the antiviral drug tenofovir that has demonstrated the potential for low, once a day dosing compared to viread and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a structure that increases its potency and selective index against hepatitis B virus. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.

Contact Information

ContraVir Pharmaceuticals, Inc.
399 Thornall Street
Edison New Jersey 08837
P:(732) 902-4000
Investor Relations:
(732) 902-4028

Employees

Shareholders

Individual stakeholders7.16%
Other institutional4.67%
Mutual fund holders3.49%

Top Executives

James E. SapirsteinChief Executive Officer & Director
John T. CavanChief Financial Officer
Robert T. FosterChief Scientific Officer
Theresa MatkovitsSenior Vice President
Sharen PyatetskayaDirector-Investor Relations